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Introduction. In a pilot study, we showed that intermittent administration of benznidazole in chronic 21 
Chagas disease patients resulted in a low rate of treatment suspension and therapeutic failure, as 22 
assessed by qPCR at the end of treatment. Herein, a three-year post-treatment follow-up study of 23 
the same cohort of patients is presented.  24 
Methods. The treatment scheme consisted of 12 doses of benznidazole at 5 mg/kg/day in two 25 
daily doses every 5 days. Parasite load, T. cruzi-specific antibodies and serum chemokine levels 26 
were measured prior to treatment and after a median follow-up of 36 months post-treatment by 27 
kDNA and SatDNA qPCR methods, conventional serological techniques and a Luminex-based 28 
assay with recombinant T. cruzi protein, and a cytometric bead array, respectively.  29 
Results. At the end of follow-up, 14 of 17 (82%) patients had negative qPCR findings, whereas 30 
three of 17 (18%) had detectable nonquantifiable findings by at least one of the qPCR techniques. 31 
A decline in parasite-specific antibodies at 12 months post-treatment was confirmed by 32 
conventional serological tests and the Luminex assays. Monocyte chemoattractant protein-1 (MCP-33 
1) levels increased after treatment, whereas monokine induced by gamma interferon (MIG) levels 34 
decreased. New post-treatment electrocardiographic abnormalities were observed in only one 35 
patient who had cardiomyopathy prior to treatment.  36 
Conclusions. Altogether, these data strengthen our previous findings by showing that the 37 
intermittent administration of benznidazole results in a low rate of treatment suspension, with 38 
comparable treatment efficacy to that of a daily dose of 5mg/kg for 60 days. 39 
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The primary clinical outcome of Trypanosoma cruzi infection is a chronic cardiomyopathy, which 44 
manifests in approximately 30% of infected individuals 10-20 years after the initial infection (World 45 
Health Organization, https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-46 
trypanosomiasis). It is estimated that approximately 1.2 million individuals are living with heart 47 
disease, making Chagas disease the most frequent cause of infectious cardiomyopathy in the 48 
world (1). Although efforts have been made in previous decades, no new compounds have been 49 
approved for the treatment of Chagas disease, with benznidazole (BZ) and nifurtimox as the only 50 
two currently available medications (2–5). Adverse events are some of the main limitations of 51 
widely applicable therapies in the chronic phase in adults (6). 52 
Although various guidelines based on randomized studies in children recommend the use of a 60-53 
day treatment schedule with BZ in adults (7), several studies have suggested that treatment 54 
outcomes do not differ between 30 and 60 days of BZ administration (8–10). Currently, in the 55 
Benznidazole New Doses Improved Treatment and Associations (BENDITA) clinical trial, BZ-56 
sparing regimens in monotherapy, including the 30 days vs. 60 days schemes, are being evaluated 57 
(ClinicalTrials.gov Identifier: NCT03378661). 58 
Furthermore, pharmacokinetic studies have shown that BZ plasma concentrations in children are 59 
markedly lower than those reported in adults, whereas the therapeutic response is higher (11, 12), 60 
adding more unresolved issues in treatment of chronic Chagas disease. Additionally, in a mouse 61 
model of chronic T. cruzi infection, reducing the overall dosage of BZ or nifurtimox using 62 
intermittent administration every five days cured the infection (13). As part of a pilot study, we 63 
previously showed that intermittent administration of BZ resulted in a low rate of treatment 64 
suspension and therapeutic failure as assessed by qPCR at the end of treatment (14). Herein, this 65 
same cohort of patients was followed up with a median of 36 months post-intermittent 66 













administration of BZ, in which the clinical status, parasite burden, T. cruzi-specific humoral 67 
responses and serum levels of chemokines were assessed.   68 
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Study population, etiological treatment and clinical follow-up. Seventeen adult patients with 71 
confirmed chronic Chagas disease [i.e., positive findings on at least two of the three serological 72 
tests, including enzyme-linked immunosorbent assay (ELISA), hemagglutination (IHA) and 73 
immunofluorescence (IIF)], aged between 28 and 57 (median, 45) years, were included (Table 1). 74 
All subjects recruited in the study provided informed consent. Patients with a history or laboratory 75 
findings compatible with liver or kidney disease, blood dyscrasias or concomitant systemic illnesses 76 
were excluded from the study. Other exclusion criteria were previous etiological treatment, 77 
pregnancy or presumption of failure in contraception during the treatment period, and location of 78 
residence that could interfere with patient participation in the study. Since arterial hypertension is a 79 
very frequent comorbidity in patients with chronic Chagas disease in our health center, this factor 80 
was not considered as an exclusion criterion. BZ was administered in intermittent doses of 5 81 
mg/kg/day, divided in two daily doses every 5 days, with a total of 12 doses, as previously reported 82 
(14). A baseline electrocardiogram (ECG) and a 2-D echocardiogram were performed to stratify the 83 
patients according to the presence or absence of cardiomyopathy (Table 1). After treatment, ECG 84 
and echocardiogram were performed yearly. Blood samples were taken prior to treatment, one 85 
week after the end of treatment, at 12 months post-treatment and yearly thereafter up to 48 months 86 
posttreatment follow up. The median time of follow up was 36 months (range 12-48 months) and 87 
the median number of samples taken per patient was five (range, two to seven samples). The 88 
study was approved by the Committee for Research and Bioethics of the Hospital Eva Peron. The 89 
latter is enrolled in the Provincial Registry for Ethics Committees accredited by the Central Ethics 90 
Committee, Ministry of Health, Buenos Aires, Argentina, dated 09/17/2010 under number 18/2010, 91 
page 54 of the Minutes Book Nº1. 92 
 93 













Assessment of qPCR for T. cruzi. Five milliliters of whole blood were mixed with an equal volume 94 
of 6 M guanidine hydrochloride buffer containing 0.2 M EDTA at pH 8.00 (GEB). After 48-72 hours 95 
at room temperature, GEB samples were boiled at 100 °C for 15 minutes and stored at 4 °C until 96 
DNA extraction and subsequent analysis by qPCR. GEB samples were centralized, codified for 97 
distribution in aliquots and sent to the two laboratories that performed the qPCR assay without 98 
knowledge of clinical data or sampling time. Each laboratory analyzed the samples in duplicate by 99 
two qPCR methods based on TaqMan technology, one directed to the conservative region of the 100 
DNA minicircle kinetoplastid (kDNA) and the other to the nuclear DNA satellite sequence 101 
(SatDNA). PCR findings were considered positive if T cruzi DNA was detectable in both 102 
laboratories by at least one qPCR assay. DNA extraction and both qPCR methods were carried out 103 
as previously described (15). The Limit of Quantification was 0.90 par. eq./mL (parasite equivalents 104 
per mL of blood) and 1.53 par. eq./mL for the kDNA and SatDNA qPCRs, respectively (15). To 105 
minimize bias, blinded control samples from seropositive and seronegative subjects were run in 106 
parallel with the study samples.  107 
 108 
Measurement of T. cruzi-specific antibodies. Serum specimens were screened for the presence 109 
of T. cruzi-specific antibodies by conventional serological tests (16) and by a Luminex-based 110 
assay, as previously described (17). All samples were processed simultaneously by the same 111 
technician and with the same reagent lots. To determine the serological treatment response in 112 
individual patients, conversion to negative findings in at least 2 of 3 conventional serologic tests, a 113 
30% reduction in ELISA titers and a 2-fold dilution by IHA or IIF were considered as significant 114 
declines in T. cruzi-specific antibodies, as previously reported (18, 19). Likewise, in the multiplex 115 
assay, the reduction of serological response to each individual T. cruzi protein was considered 116 
significant if the mean fluorescence intensity (MFI) declined by 50% relative to that of a pre-therapy 117 
sample assessed concurrently (20). 118 














Cytometric bead array (CBA). CBA assays with sera samples were conducted for IL-8, Interferon 120 
γ-induced protein 10 (IP-10), monocyte chemoattractant protein-1 ( MCP-1 ), monokine induced by 121 
gamma interferon (MIG) and regulated on activation, normal T cell expressed and secreted  122 
(RANTES), according to the manufacturer’s instructions (BD Biosciences Franklin Lakes, NJ,  123 
USA). The samples were acquired on a FACSCalibur flow cytometer and were analyzed using 124 
FACSComp Software v1.4 (BD, Franklin Lakes, NJ, USA). 125 
 126 
Statistical Analysis. The normality of the variable distribution was assessed using the 127 
Kolmogorov-Smirnov criterion. Data from descriptive statistics, such as the proportions of the total 128 
and percentages and median, were determined as appropriate. Qualitative pre- and post-treatment 129 
PCR findings were compared by the McNemar test. Differences in chemokine levels between T. 130 
cruzi-infected and uninfected subjects were evaluated by the Mann-Whitney U-test. Changes in T. 131 
cruzi-specific antibodies and chemokine levels during post-treatment follow-up were evaluated with 132 
an ANOVA for repeated measures with the available data. To analyze changes in the levels of T. 133 
cruzi-specific antibodies measured by IHA and IIF, the ANOVA for repeated measures was 134 
performed after log transformation of the data. Statistical analysis was conducted using the 135 
Analytical Software Statistix v8.0 (Analytical Software, Tallahassee, FL, USA) and GraphPad Prism 136 
v8.0.1 (GraphPad Software, San Diego, CA, USA). 137 
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Clinical characteristics of patients in the study.  140 
We previously published a pilot study to assess the safety and short-term efficacy of a scheme of 141 
intermittent administration of BZ in patients chronically infected with T. cruzi (14). Seventeen of the 142 
20 patients recruited in our former study were followed for a median period of three years (range, 143 
12-48 months) after BZ administration. Eleven of the 17 (65%) patients recruited had no 144 
electrocardiographic or echocardiographic alterations at baseline (Table 1). Ten of the eleven 145 
patients without cardiomyopathy remained stable during follow-up, while the remaining patient (i.e., 146 
Patient I14 of Table 1) showed basal inferior hypokinesis of the left ventricle at 36 months post-147 
treatment without significant changes in the ECG. Five of the 17 (35%) patients showed mild 148 
cardiomyopathy prior to treatment (i.e., two subjects with conduction disturbances [i.e., Patient I8 149 
and I9 of Table 1], one subject with both conduction and rhythm disturbances [i.e., Patient I4] and 150 
two subjects with ventricular arrythmia [i.e., Patient I3 and Patient I10]. Of note, Patient I10, who 151 
had arterial hypertension as a comorbidity, developed diastolic dysfunction as assessed by 152 
echocardiography during follow-up (Table 1). The remaining subject showed repolarization 153 
abnormalities of the inferior left ventricle wall (i.e., Patient I20) not related to Chagas disease and 154 
presented a mild mitral insufficiency at the end of follow-up.  155 
 156 
PCR monitoring.  157 
Fourteen of the 17 (82%) patients showed no detectable T. cruzi DNA either by kDNA (Fig. 1A) or 158 
SatDNA (Fig. 1B) qPCR methods at the end of follow-up, while three (18%) patients had positive 159 
qPCR results (Fig. 1A).The only patient who showed positive qPCR findings at the end of treatment 160 
had no detectable results by either qPCR method from 12 months until the end of post-treatment 161 
follow up (Fig. 1A and 1B). During post-treatment follow-up, all positive qPCR samples gave 162 
parasitic loads below the Limit of Quantification for both qPCR methods. Two of the seven patients 163 













with no detectable qPCR findings at baseline had positive results at the end of follow-up, while the 164 
remaining five patients showed no detectable qPCR results throughout the post-treatment follow-165 
up. Fourteen out of the 15 subjects followed up until 36 months posttreatment had at least three 166 
samples tested during the follow-up period. As a whole, the proportion of subjects with positive 167 
kDNA/SatDNA qPCR of the total evaluated significantly decreased over time post-treatment (i.e., t0, 168 
10/17 vs. t2, 1/16, P=0.0014; vs. t12, 0/16, P= 0.0002; vs. t24, 0/10, P<0.0001; vs. t36, 3/15 P=0.025).  169 
 170 
T. cruzi-specific humoral response following intermittent administration of BZ.  171 
The levels of T. cruzi-specific antibodies measured by conventional techniques significantly 172 
declined 12 months following treatment by ELISA (Fig. 2A) and at 24 months post-treatment by IHA 173 
(Fig. 2B) and IIF (Fig. 2C). As defined in the Material and Methods, at an individual basis, seven of 174 
16 (43.75%) patients had a decrease in the levels of T. cruzi-specific antibodies by ELISA (Fig. 175 
2A), four of 17 (23.53%) by IHA (Fig. 2B) and seven of 17 (42.18%) by IIF (Fig. 2C). The multiplex 176 
assay to measure antibodies against a set of 10 T. cruzi-derived recombinant proteins was 177 
conducted in 14 of the 17 patients treated with intermittent BZ. Twelve of the 14 (85.71%) patients 178 
with baseline reactive serum by the Luminex-based multiplex assay showed significant decreases 179 
in the reactivity to one or more proteins following intermittent administration of BZ (Fig. 3, Fig. S1).  180 
 181 
Monitoring of inflammatory cytokines. Serum levels of IL-8, IP-10, MCP-1, MIG and RANTES 182 
were measured prior to and after a median period of 36 months after intermittent administration 183 
with benznidazole. Prior to treatment, MCP-1 levels were increased, and MIG levels were 184 
decreased in T. cruzi-infected subjects compared with uninfected subjects (Fig. 4). These 185 
alterations in chemokine levels reverted following drug therapy, with an increase in MCP-1 levels 186 
and a decline in MIG levels. No significant changes were observed in serum levels of IL-8, IP-10 or 187 
RANTES (P > 0.05).   188 














Most pharmacokinetic and pharmacodynamic studies have shown that patients with lower plasma 190 
BZ levels can achieve an appropriate parasitological response (21), even among those who cannot 191 
complete treatment due to adverse events (22, 23). Herein, we report that the parasitological 192 
response in a group of patients treated with BZ administered every five days and followed for a 193 
median period of three years was in the same range as that observed with the standard daily dose 194 
(4, 24, 25). In a seven-year follow-up study of chronic Chagas disease patients living in an area 195 
non-endemic for T. cruzi infection treated with BZ as monotherapy, the rate of parasitological 196 
response measured by kDNA qPCR was 90% (25) measured one year after treatment. A lower 197 
rate of parasitological response was observed in the BENEFIT (Benznidazole Evaluation For 198 
Interrupting Trypanosomiasis Trial) clinical trial, in which chronic Chagas disease patients with 199 
cardiomyopathy received BZ monotherapy, with 55.4% of patients with negative qPCR findings at 200 
two years post-treatment and 46.7% at five or more years (24). In another study assessing the 201 
efficacy of three oral E1224 (a water-soluble ravuconazole prodrug) regimens and benznidazole 202 
versus placebo in adult chronic indeterminate Chagas disease, the rate of parasitological response 203 
with BZ was 82% at 12 months post-treatment by SatDNA qPCR (4).  204 
 205 
In our study, one patient presented early therapeutic failure at the end of treatment but achieved no 206 
detectable PCR results at later time points. Of the remaining 16 patients, 13 had no detectable 207 
parasite DNA throughout the post-treatment follow up period by both qPCR methods, and three 208 
showed detectable PCR at the end of follow-up. These findings, and concordant results from other 209 
authors showing a high rate of undetectable levels by PCR after one year post-treatment (3, 4, 25), 210 
raise the question about the optimal time length required to assess treatment efficacy. It is worth 211 
noting that, in addition to implementing a longer follow-up period, we applied two qPCR methods 212 
that use two different molecular targets as recommended for confirmatory purposes (26, 27), and 213 













the sample analysis was performed in two different laboratories.. We observed 6% discordancy 214 
between the two qPCR methods and 6% discordancy between the laboratories. Discordancy 215 
occurred between samples in which the parasitic loads were near the limit of detection of the 216 
corresponding methods. This can be expected since qPCR precision diminishes at low parasitic 217 
loads (15). One limitation of this study is that the patients were not followed during the same time 218 
interval, and as consequence the number of follow-up samples was also different among patients. 219 
 220 
Recently, non-replicating intracellular T. cruzi amastigotes, considered dormant, were 221 
demonstrated to be resistant to extended drug treatment in vivo and in vitro and could re-establish 222 
a growing infection after drug exposure (28). Dormancy could be a factor for treatment failure since 223 
BZ requires metabolic activation to exert its trypanocidal effect. Therefore, it is important to keep 224 
the plasma concentrations of the drug within the accepted therapeutic range and to guarantee that 225 
all dormant parasites are eliminated (12, 28). The fact that intermittent BZ administration allowed a 226 
five-fold reduction of the standard daily dose of 5 mg/kg/day per 60 days (5) opens the possibility of 227 
extending the length of drug administration, eventually targeting dormant parasites which might re-228 
initiate replication (28). It is also likely that the lower frequency of dosing every five days avoids the 229 
accumulation of toxic metabolites of BZ, thus reducing the severity of adverse events (14). 230 
 231 
The efficacy of intermittent BZ administration was also reflected by the decrease in T. cruzi-specific 232 
antibodies, either by conventional serologic tests or the multiplex assay, to the same extent as that 233 
observed in our previous study with daily BZ doses for 30 days (18). Although 36 months is a short 234 
period of time to assess disease progression, it is of note that the two patients who showed 235 
echocardiographic changes during follow-up had presented cardiac alterations prior to treatment. 236 
Of note, one of these patients had arterial hypertension which is one of the most frequent 237 
comorbidities (29, 30) and a risk factor for heart failure (31) in chronic Chagas disease. 238 













Chronic T. cruzi infection leads to an inflammatory process that keeps the parasite under control 239 
but can also induce tissue damage. Patients with chronic Chagas disease with cardiac involvement 240 
show a higher level of pro-inflammatory cytokines compared with patients without cardiac disease 241 
(32). Moreover, T. cruzi-infected patients with chronic heart disease and arterial hypertension have 242 
increased plasma levels of pro-inflammatory cytokines compared with patients without 243 
hypertension (33). Chemokines have been identified as regulators of leukocyte trafficking during 244 
the different phases of both innate and adaptive immune responses (34). MCP-1, which 245 
participates in the recruitment of monocytes, memory T cells and dendritic cells, exerts its effects 246 
through binding to G-protein-coupled receptors on the surface of activated leukocytes. The 247 
decreased levels of MCP-1 found in untreated T. cruzi-infected subjects compared with uninfected 248 
controls may reflect an increased consumption of this chemokine during chronic infection (35), 249 
while the restoration of its levels following treatment reflects a decrease in leukocyte activation. In 250 
agreement with these findings, a decrease in macrophage activation following treatment with BZ 251 
has been reported (36, 37). In contrast, serum levels of MIG, which induces migration of activated 252 
T cells (38), decreased after the intermittent administration of BZ compared to pretreatment levels. 253 
This result is consistent with the early decrease of IFN-γ-producing cells observed in T. cruzi-254 
infected subjects treated with the standard BZ scheme that can be followed by a reemergence of 255 
polyfunctional IFN-γ-producing cells (19, 20, 39, 40). In summary, the findings of this pilot study 256 
provide a basis for further exploration of treatment schemes with intermittent administration of BZ. 257 
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Tables and Figure Legends 422 
Table 1. Clinical characteristics of the study population at baseline and following 423 
intermittent administration of BZ.  424 
    
ECG  
 
Echocardiogram Cardiac  
Basal at the end  Basal at the end of  disease 
ID Gender Age ECG of follow-up  Echocardiogram follow-up Progression A 
I2 F 53 Normal Normal Normal Normal No  
I3 F 42 VA VA LVSD 60/apical  LVSD 50/apical  No  
     dyskinesis dyskinesis  
I4 F 45 LAFB/VA LAFB/VA Normal Normal No  
I6 F 32 Normal Normal Normal Normal No 
I8 M 57 RRBB RRBB Normal Normal No 
I9 M 55 RRBB/LAFB RRBB/LAFB Septal Septal No 
     hypertrophy, hypertrophy,  
     LVH LVH  
I10 F 41 VA VA MMI MMI and  No B 
      diastolic  
      dysfunction  
I11 F 46 Normal Normal Normal Normal No B 
I12 F 49 Normal Normal Normal Normal No B 
I13 M 49 Normal Normal Normal Normal No 
I14 M 46 Normal Normal Normal Inferior basal  Yes (basal inferior  
      hypokinesis hypokinesis) 
I15 M 28 Normal Normal Normal Normal No 













I16 F 40 Normal Normal Normal Normal No 
I17 M 35 Normal Normal Normal Normal 
No 
I18 M 45 Normal Normal Normal Normal 
No 
I19 F 33 Normal Normal Normal Normal 
No 
I20 M 43 Repolarization Repolarization Normal MLAD Yes (not related  
   abnormalities abnormalities   with Chagas  
       disease) 
 
425 
 A Disease progression was defined by the development of new electrocardiographic or 426 
echocardiographic alterations related to Chagas disease. B Patient with arterial hypertension prior 427 
to treatment. LAFB, Left Anterior Fascicular Block; LVH, Left Ventricular Hypertrophy; LVSD, Left 428 
Ventricular Systolic Diameter; MMI, Mild Mitral Insufficiency; MLAD, Mild Left Auricular Dilatation; 429 
RRBB, Complete Right Bundle Branch Block; VA, Ventricular Extrasystoles. 430 
  431 













Fig. 1. Monitoring of parasitological response following intermittent administration of BZ. 432 
Blood samples collected prior to treatment and at several post-treatment time-points were analyzed 433 
by T. cruzi kDNA and SatDNA qPCR assays. Blood samples of uninfected subjects were tested as 434 
controls. Each circle represents the maximum qPCR value for each patient at each time-point. 435 
Dotted lines represent the limit of detection of each qPCR method, 0.90 and 1.53 par. eq./mL for 436 
kDNA and SatDNA qPCRs, respectively. ND, no detectable; DNQ, detectable but non-quantifiable.  437 
 438 
Fig. 2. Monitoring of T. cruzi-specific antibodies by conventional serological tests following 439 
intermittent treatment with BZ. T. cruzi-specific antibodies, as determined by ELISA, IHA and IIF, 440 
were measured prior to treatment and at different time-points after completion of BZ administration. 441 
Each open circle represents the data for single subjects. Broken horizontal lines show the reactivity 442 
threshold for each serological test. ***P< 0.001, **P< 0.01 and * P < 0.05 versus pretreatment 443 
levels (time 0) by ANOVA for repeated measures after log transformation of the IHA and IIF data. 444 
Black square symbols indicate decreased reactivity compared with baseline reactivity, as defined in 445 
the Materials and Methods. 446 
Fig. 3. T. cruzi-specific humoral response measured by multiplex assay in chronic Chagas 447 
disease patients after intermittent administration of BZ. Plots exhibit representative data for 448 
single subjects for the different proteins assessed. Each point represents the mean fluorescence 449 
intensity (MFI) for reactive proteins out of 10 assessed, analyzed both prior to treatment (time 0) 450 
and at several post-treatment time-points. *** P < 0.001, ** P < 0.01 and * P < 0.05 versus 451 
pretreatment levels (time 0) by ANOVA for repeated measures. 452 
Fig. 4. Sera levels of MCP-1 and MIG in chronic Chagas disease patients treated with 453 
intermittent doses of BZ. A cytometric bead array was used to measure the concentrations of 454 
chemokines in the sera of subjects with chronic T. cruzi infection (circles) at different time points 455 













following intermittent administration of BZ and in uninfected subjects (triangles). Changes from 456 
baseline (time 0) were assessed using ANOVA for repeated measures. ** and ≠≠ P < 0.01 versus 457 
baseline (time 0); * P < 0.05 versus baseline. The horizontal line in uninfected subjects shows the 458 
median values.  459 
 460 
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